重药控股(000950.SZ):上半年净利降35.31%至3亿元
格隆汇 8 月 24日丨重药控股(000950.SZ)披露2020年半年度报告,实现营业收入170.65亿元,同比增长5.30%;归属于上市公司股东的净利润3亿元,同比下降35.31%;归属于上市公司股东的扣除非经常性损益的净利润2.93亿元,同比下降32.05%;基本每股收益0.17元。
1、进一步健全全国商业网络布局。报告期内,成功布局安徽、吉林、内蒙三地,有效夯实全国战略布局;天士营销商业并购项目、四川人福项目即将落地;有序推进其他省份并购项目。
2、在新一轮带量采购中,集采模式效果继续凸显。31个品规中30个落户公司,独家点配占比近60%;25个首批GPO续标品种100%落户集团总部;在中国上市的25个新药实现100%落户;促成中国医药-重庆医药商业联合体企业在重点供应商实现一、二级开户23家。
3、“医药+互联网”探索成效显著。报告期内,公司持续践行“两网互动”战略,在“医药+互联网”方面展现新的成果。自主开发的电子处方平台在160余家药房上线,开具处方1万余张;与重庆市急救中心、重医附二院、永川医院互联网医院合作,有效拓宽处方药销售渠道,增强与医院的粘性;和平药房启动直播销售、上线微商城,探索线上线下相结合的全渠道运营。
4、医药研发板块取得较大进展。稳步推进新品研发,有望实现自2021年起持续有创新产品上市的良性发展节奏。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.